Effetti del Filgotinib, Inibitore Selettivo di JAK1 , con e senza Methotrexate in Pazienti con Artrite Reumatoide: Risultati Riportati dai Pazienti
Arthritis Res Ther 2018; 20(1):57 doi: 10.1186/s13075-018-1541-z
Patient-reported outcomes (PROs) from two, Phase 2b, filgotinib (FIL) studies, DARWIN 1 and 2, revealed that patients receiving FIL had improved and sustained PRO responses compared with placebo. With suboptimal RA treatment, patients lose joint functional ability, which heavily influences patient quality of life. The previously reported data from the DARWIN studies, concluded that patients given FIL achieved clinically relevant dose-dependent improvements compared with patients given placebo¹,²...